Literature DB >> 22814805

More on a patient-centric approach in the anti-VEGF therapy.

A Grzybowski, F J Ascaso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22814805      PMCID： PMC3470047          DOI： 10.1038/eye.2012.148

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Authors:  Adnan Tufail; Praveen J Patel; Catherine Egan; Philip Hykin; Lyndon da Cruz; Zdenek Gregor; Jonathan Dowler; Mohammed A Majid; Clare Bailey; Quresh Mohamed; Robert Johnston; Catey Bunce; Wen Xing
Journal:  BMJ       Date:  2010-06-09

2.  Bevacizumab versus ranibizumab for AMD.

Authors:  Philip J Rosenfeld
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

3.  Avastin doesn't blind people, people blind people.

Authors:  Serafin Gonzalez; Philip J Rosenfeld; Michael W Stewart; Jennifer Brown; Steven P Murphy
Journal:  Am J Ophthalmol       Date:  2012-02       Impact factor: 5.258

4.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

Review 5.  Management of retinal vascular diseases: a patient-centric approach.

Authors:  C S Brand
Journal:  Eye (Lond)       Date:  2012-04       Impact factor: 3.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.